Table 1.
Demographic and clinical characteristics at RCP entry of patients included in the OLE analysis set
| Characteristic | Ravulizumab–ravulizumaba (n = 78) |
Placebo–ravulizumabb (n = 83) | All patients (N = 161) |
|---|---|---|---|
| Female, n (%) | 40 (51.3) | 42 (50.6) | 82 (50.9) |
| Age, years, mean ± SD | 58.2 ± 13.6 | 53.6 ± 16.4 | 55.9 ± 15.2 |
| Race, n (%) | |||
| White | 61 (78.2) | 57 (68.7) | 118 (73.3) |
| Asian | 13 (16.7) | 14 (16.9) | 27 (16.8) |
| Black or African American | 2 (2.6) | 4 (4.8) | 6 (3.7) |
| Other/unknown/not reported | 2 (2.6) | 8 (9.6) | 10 (6.2) |
| MGFA clinical classification, n (%) | |||
| Class IIa/b | 36 (46.2) | 35 (42.2) | 71 (44.1) |
| Class IIIa/b | 37 (47.4) | 43 (51.8) | 80 (49.7) |
| Class IVa/b | 5 (6.4) | 5 (6.0) | 10 (6.2) |
| MG-ADL total score, mean ± SD | 9.2 ± 2.6 | 8.9 ± 2.2 | 9.0 ± 2.4 |
| QMG total score, mean ± SD | 14.8 ± 5.2 | 14.3 ± 5.2 | 14.5 ± 5.2 |
MG-ADL, Myasthenia Gravis–Activities of Daily Living; MGFA, Myasthenia Gravis Foundation of America; OLE, open-label extension; QMG, Quantitative Myasthenia Gravis; RCP, randomized controlled period; SD, standard deviation
aPatients treated with ravulizumab during both the RCP and OLE. bPatients treated with placebo during the RCP and ravulizumab during the OLE